click contribut analyst contact
report provid updat view
biotech sector refresh initi outlook link base
state sector overal believ innov
smid/mid-cap compani highli special area less
suscept price pressur select under-valued larger-
cap name fare best ye given low likelihood
initi resurg activ would enough
off-set concern polit rhetor slow growth increas
competit patent cliff continu weigh
fast start earli momentum quickli
fizzl pick slightli renew activ
sector particularli smid-cap benefit first week
year spate transact help re-ignit
enthusiasm come broader market weak howev
sinc mid-januari valuat larg revert biotech
sinc under-perform broader market larg pharma
 activ wane though recent pick back polit
nois around drug price increas major catalyst
neg biib aducanumab drug launch mix gild yescarta
accept sector under-valued limit enthusiasm investor
slight increas bullish around valuat still
expect increas exposur due enthusiasm prospect
innov also broad belief biotech under-perform
broader market part due increas polit pressur
balanc year remain neutral sector see
stock picker market large-cap valuat continu
look inexpens rel pharma small/smid-cap could maintain
momentum recent a-rel bump expect
innov technolog continu draw capit early-stag
earn even face season headwind commerci execut
remain good remaind year said
bar gotten lower near-term expect earn growth
among large-cap biotech come consider long-
enbrel pipelin diversif remain flip side
expect high-scienc smid/mid-cap compani high
stock valuat often alreadi reflect mani key
continu page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
requir non-u analyst conflict disclosur see page
layer onto likelihood increas polit rhetor around drug price potenti
increment polici action elect would expect see
major uptick generalist interest need drive meaning sector momentum
said still see numer valuat disconnect among individu stock believ
drug cost contain initi like remain key stori
polici discuss among democrat presidenti candid newli mint
democrat major hous increas significantli larg center
aspect healthcar insur coverag medicar specif
transform drug cost control addit polici enact current administr
 shame list dtc advertis price disclosur medicar protect list chang etc
gener limit financi consequ commerci biopharma compani despit
howev believ potenti headlin risk presidenti campaign like pivot
toward easy-to-convey reson issu pharmaceut price well
increas evid heavi discount crowd space hcv cgrp persist
eu scrutini class uk vrtx cf product may much overcom
face headwind well long-term growth pressur caus lower
price flexibl patent cliff see increas import fundament
broader sector driver pipelin setback biib aducanumab alzheim
gild selonsertib nash competit threat biib core sma/m franchis
inflammation/rheumatolog space highlight need pharma
shown desir diversifi hefti acquisit far year especi gene therapi
oncolog recent howev compani put forth mix messag regard
urgenc desir smaller bolt-on deal partnership biib nite merck tilo
gild/novo vrtx exon vs transform acquisit believ would necessari
drive broader posit sector momentum though key personnel may place
effect impact transact
innov continu shine brightli overal regulatori landscap remain
favor despit increment neg follow promis data
eha confer bispecif precis oncolog small molecul like
continu resurg gene therapi remain high profil regulatori
endors nvss zolgensma help lay reimburs framework futur
agent cours integr launch zolgensma meet expect order
maintain enthusiasm gene therapi space overal becom satur investor
need close scrutin extent clinic manufactur de-risk emerg
program see chang trend once-hot area like immuno-oncolog car-
give way mrna gene edit neurolog apart alzheim inflamm/rheum/
derm innov remain rampant regulatori environ remain rel
permiss foster faster develop pathway greater flexibl clinic trial design
maintain commun collabor relationship industri help
compani differenti products/technolog progress market
unlik chang significantli new fda leadership though note recent
develop reject imgn mirvetuximab neg selinexor brief doc
stringent nash guidanc illustr bar remain high
backdrop launch remain mix sector-mov catalyst expect
select high-scienc focus smid/mid cap name clinic regulatori event
perceiv insul price concern perform best launch new cgrp drug
mix strong uptak part due free drug program ultim
convers remain uncertain greater discount expect car-t uptak
remain gradual uptak agent like gild yescarta remain cap
infrastructur requir reimburs complex cancer drug nerlynx
adcetri disappoint well bright spot like gild
biktarvi regn dupix biib spinraza acad nuplazid though
market time expect like alreadi caught see
complex administration/reimburs two
major launch nvss zolgensma sage zulresso like moder adopt
major launch driver akin major sector-driv launch year past like harvoni
tecfidera likewis biib aducanumab alzheim data past neg
fewer expect clinic catalyst could reverber throughout sector
though updat ip amgn enbrel biib tecfidera could broadli influenc
overal confid large-cap revenu sustainability/lif cycl posit neg still
sector-driv launch catalyst limit still see favor reward/risk
and/or regulatori feedback also continu view
certain large-cap provid rel safeti underappreci growth
tabl content click navig
review outlook
summari view
biotech coverag univers
theme earn growth
top idea
learn think
mid-cap biotech subsector outperform broader market large-cap biotech
continu lag behind
macro factor interest rate trade uncertainti key pipelin failur large-cap
aducanumab selonsertib like drove under-perform investor turn
smaller biotech and/or sector
mid-cap outperform far help enthusiasm posit data readout small-
cap trade mostli line ytd
price exclud acquir compani
outlook neutral balanc competit growth headwind alongsid tangibl
manifest drug price contain potenti mitig enthusiasm
remain neutral posit new biotech leadership visibl revenu growth sever
biotech off-set increas competit threat less permiss regulatori environ
compar one tailwind look less favor key headwind worsen one
neutral factor improv anoth key headwind begun eas
bullishslightli bullishneutralneutr headwindsneutralslightli bearishslightli bearishslightli bearish tailwindsslighli bullishbullishslightli bullishslightli price policyslightli bearishneutralslightli bearishslightli bearishcompetitionslightli bearishslightli bearishslightli bearishveri bearishpat cliffsslightli bullishneutralneutralneutralregulatori landscapeveri bullishveri bullishveri bullishslightli bullishtherapeut area emergenceveri bullishveri bullishveri bullishveri bullishhuman capit -- neutralslightli bullishm aslightli bullishslightli bearishveri bullishveri bullishearn growthslightli bearishveri bearishveri bearishslightli bearishfinanc environmentslightli bullishveri bullishneutralneutralsentimentneutralslightli bearishneutralneutr biotech outlook halftim report tide lift boat
summari view key sector headwind tailwind
competit -- competit biotech spur new fda
approv brand biosimilar product payer initi aggress
discount market cgrp anti-vegf
remain headwind sector expect trend continu
intensifi across sector addit entrant payer leverag
competit dynam reduc drug cost
earn growth -- long-term growth prospect look promis
mid-cap biotech large-cap compani larger biotech continu
work grow pipelin contribut larger revenu base though current
valuat among mani commercial-stag compani still look like
may overli discount dynam
drug price polici -- administr continu aggress
approach drug price multipl govern committe hear
taken place topic recent continu believ draconian chang
reimport central part negoti etc unlik
said self-pol evid alreadi account
decreas abil use drug price lever growth go forward
percept around increas rhetor elect even
like amount major chang like continu keep mani investor
sidelin
sentiment -- despit sens gener optim among investor enter
year sentiment base survey appear declin somewhat
despit significantli increas activ attract valuat investor
remain optimist innov continu fuel sector
growth overwhelmingli neg specialist generalist
overhang polit rhetor look clariti becom
construct space
innov -- core fundament driver biotech sector d-fuel
innov remain intact believ high profil setback alzheim
nash put greater onu innov larger biotech like
invest compani creation overal continu
flow healthi pace innov perceiv occur small/mid-
cap biotech larg pharma within large-cap biotech
 -- believ rel strateg capit deploy strong cash
posit pipelin need improv manag stabil continu
support activ though believ predict major deal remain difficult
major smaller earlier-stag bolt-on light favor
valuat -- may suffici
catalyz sustain sector
capit -- may necessarili enough complet turn
sector sentiment around influx new manag member larger
biotech gener well receiv becom
establish respect compani provid fresh perspect
strateg clariti believ help foster improv capit alloc
portfolio diversif continu see manag premium
place smaller-cap compani
regulatori landscap -- overal regulatori trend continu look
favor given clear continu push fda new treatment
modal gene therapi option patient slightli
cautiou regulatori environ remaind
given chang leadership potenti restrict guidanc
novel therapi approv nash somewhat less favor trend
approv volum though overal still see current environ
patent cliff -- advanc key life cycl manag strategi
strateg transact ip lawsuit settlement remain pertin patent
cliff inch closer believ increasingli imper large-cap compani
make substanti progress life cycl pipelin develop
posit side favor uspto polici help brand drug
manufactur better defend patent portfolio time
financ environ -- ipo market activ continu robust
notabl shift toward high-opportun therapeut area
strong valuat even though post-ipo perform mix overal
public privat invest space remain strong bode well
continu innov fund new technolog
decreas privat invest oversatur remain risk watch
year biotech sell-sid experi
yea biotech sell-sid experi
md brown medic school ba
md albert einstein colleg
previous cover biotechnolog
biolog brown univers
sector credit suiss
pursu special medic train
phd biochemistri ucla
ba colorado colleg
bs molecular biophys biochemistri
yale univers
interest scienc medicin anyth
manag consult booz co
pharma pbm/servic bd experi
virolog
year biotech sell-sid experi
phd pharmaceut scienc
bs/ba doubl degre neurosci
team abraham jefferi
medic univers
econom univers pittsburgh
prior work ip law preclin drug
prior tenure-track associ professor
develop bioinformat research
univers virginia
conduct biomed research
ms patent law univers
bs doubl major biochemistri
univers minnesota
support research inflamm
join abraham biotech equiti
research team
prior buy-sid experi ny hedg
fund focus therapeut
join abraham biotech equiti
research team
immunolog
allergi asthma
mbb india institut medic
phd biolog scienc special
year biopharma competit
intellig healthcar consult
experi sagient informa
ba econom uc san diego
join mackay biotech equiti research
team
clinic biomed research
experi aiim john hopkin
biophys carnegi mellon
ms biochemistri oncolog
concentr univers nebraska
prior experi alvarez marsal
bs biolog zhejiang univers
biotechnolog equiti research mizuho
join mackay biotech equiti research
team
prior experi healthcar invest
join mackay biotech equiti research
team
price
stock coverag across three analyst team span cap size numer therapeut area
year cumul sell-sid research experi across franchis
graduate-level profession degre industri expertis across scientif research drug develop clinic medicin payer price
reimburs commerci strategi market analyt busi develop financ intellectu properti regulatori
pharmaci distribut suppli chain
compon rbc comprehens healthcar research cover key core subsector
top idea
abraham op tgt share look inexpens us bullish long-term
sustain core hiv franchis littl valu reflect share pipelin visibl toward
earn stabil believ stage set well new ceo oday pursu strateg initi drive
mackay op tgt believ core complement franchis secur given impress
switch us pnh patient soliri ultomiri mid-april driven ultomiri superior clinic profil
ahead biosimilar entri eu ip expir us ip expir pipelin asset
wilson diseas al amyloidosi gmg waiha high unmet need diseas
underappreci street upsid come ultomiri opportun neurolog indic
ms al
abraham op tgt think stock reflect much skeptic futur nash market
strong ph iii regener data favor physician reaction oca profil adopt expect
see out-year potenti oca expect share appreci becom better recogn
mackay op tgt remain bullish adcetri commerci opportun hodgkin
lymphoma despit sale weak enfortumab vedotin ev demonstr high respons rate
orr bladder cancer registr data support acceler approv bla
submiss top-line data tucatinib metastat breast cancer tisotumab vedotin
tv cervic cancer would help diversifi franchis away adcetri
top idea continu
abraham op tgt believ opportun potenti transform
therapi
depress possibl anxiety/sleep disord could help drive out-year revenu degre
de-risk program low regulatori bar physician recept underappreci believ continu
progress underappreci remain pipelin initi get color
upcom day help drive upsid share
abraham op tgt believ recent demonstr microdystrophin limb girdl gene
therapi combin out-year potenti clinic activ accept safeti along signific
invest gene therapi manufactur capac technolog talent establish emerg leader
gene therapi space current level think stock fulli reflect promis larg gene therapi
pipelin solid grow revenu foundat provid exon skip portfolio
hnsa ss karamanoli op tp sek tgt believ hansa biopharma repres attract opportun within
multipl indic novel immunomodulatori enzym imlifidas bullish approv within highli sensit
kidney transplant candid given efficaci safeti profil drug high unmet need time
effect desensit treatment see valu inflect point approach eu regulatori decis
follow-on fda discuss potenti bla file
mackay op tgt see oraxol ticket brand drug market anticip oraxol
on-going mbc trial read posit non-inferior vs iv paclitaxel potenti show superior see larg
market oral chemotherapi anticip move toward oncolog care model ocm futur could
encourag use oral oncolyt vs iv
mph ln karamanoli op gbp tgt believ market miscalcul risk-reward profil mereo
compani sever shot goal posit cohort data month studi asset adult
osteogenesi imperfecta remov clinic risk confid see posit outcom
next data-point month underappreci potenti rare diseas drug
arql renza op tgt believ arql precision-bas kinas inhibitor small molecul portfolio oncolog
rare diseas led revers btki arq hold consider promis follow impress ph b-cell data eha
continu news flow year expect de-risk momentum continu set long-term share
reevalu top theme look
investor survey indic slightli decreas optim go
investor maintain increas posit
larg
biotech sector
despit
under-perform
expect
launch clinic data catalyst lesser degre favor
financ regulatori environ key posit driver
increas sector theme
larg seen play first half
total deal valu includ bmi pend offer celg pfe
offer array lli acquisit loxo oncolog rog
pend buy-out vrtx offer exon
despit robust occurr activ generalist fund
still hesit
like due polit
rhetor around healthcar cost contain initi weigh
sector primari season kick
re-ent sector
polit pressur drug price increas constant
regard aggress cost contain measur stymi
investor enthusiasm across sector far away biggest
concern cite investor specialist generalist go
second half
beyond drug price rhetor potenti overhaul sector sentiment
next largest concern investor underscor major
respond expect sector under-perform
expect under-perform come despit roughli
even split investor expect increas exposur
vs decreas exposur see sector
under-valued vs overvalu given healthcar reform
popular role polit footbal see sentiment continu weigh
heavili sector least medium term absenc
take despit sens gener optim among investor enter year sentiment base survey appear
declin somewhat despit significantli increas activ attract valuat investor remain optimist
innov continu fuel sector growth overwhelmingli neg specialist generalist overhang polit
rhetor look clariti becom construct space
survey investor gaug sentiment go
long-onli would describ invest strategi biotech outlook halftim report tide lift boat
investor split almost evenli see sector overvalu vs under-valued
head specialist lean toward under-valued
believ reflect mix sentiment space lean posit
investor sentiment shift
bullish territori vs
survey
investor shift fairli
valu under-valued
among sector specialist
long-short investor bullish
sector long-onli
current view biotech sector rel broader generalistlong-onli specialistlong-short generalistlong-short current view biotech sector rel broader market overvaluedfairli valuedundervalu despit slightli bullish sentiment investor still expect biotech under-perform broader
market suggest expect increas polit pressur weigh sector
investor sentiment shift bearish vs broader market across three survey categori
fewer investor expect out-
in-lin perform vs
investor shift
expect
under-perform
major investor type
survey expect sector
under-perform back half
 in-lin expect biotech sector perform rel broader market next three generalistlong-onli specialistlong-short generalistlong-short expect biotech sector perform rel broader market next three month outperform in-lin biotech outlook halftim report tide lift boat
major investor plan maintain posit
though investor plan increas exposur vs suggest appetit take advantag
what seen misvalu sector
investor sentiment shift
prior survey littl
chang investor plan
decreas hold
onli larg content
wait
long-short investor plan
increas exposur vs
expect increas maintain decreas net exposur biotech sector next three generalistlong-onli specialistlong-short generalistlong-short expect increas maintain decreas net exposur biotech sector next three month increasemaintaindecreas biotech outlook halftim report tide lift boat
investor look toward prospect drive perform drug price
concern remain preval overhang
investor remain optimist prospect new therapeut area emerg drive sector
growth
drug price polici remain front-of-mind concern like due presid recent promis unveil
new healthcar plan come month democrat primari kick next week
price policycompetitionsentimentearn growth valuationpat cliffshuman capitalregulatori landscapefinanc environmentinnovationm ainvestor select biggest posit neg driversbiggestheadwind neg driver biggesttailwind posit averagebiggest tailwind positivedriv biggest headwind neg driver biotech outlook halftim report tide lift boat
littl consensu among favorit large-cap though investor tend favor
far prefer large-cap among generalist sit top pick specialist
next favor among specialist
least prefer large-cap among investor survey
materi trend less like
fda commission scott gottlieb continu advanc project
believ favor overal landscap drug approv instanc
recent announc use real-world data rwd could
implic medic use off-label potenti make easier add
indic broaden clinic use addit agenc
pursu robust rapid guidanc develop aid clarifi new drug
develop pathway eas use/access
increas flexibl around label design includ broad indic
agnost label basket approach increasingli favor
number approv nme orphan drug design approv
percentag applic approv increas year-over-year among
product approv year sever cgrp treatment migrain
prophylaxi aimovig ajovi emgal well spark luxturna first
vivo gene therapi approv gild biktarvi rapidli grow hiv
treatment gene therapi particular interest track
expect
new
modal potenti benefit compani like
increasingli favor regulatori pathway
fda place increas emphasi speed-to-market perhap best
demonstr sgen approv adcetri via rtor real-tim
oncolog review though read gener competit
well see net posit sector new therapi could
potenti face fewer barrier order reach market
discuss detail competit section increas number
product approv quickli lead increas competit though
fda directli regul price drug commission gottlieb
believ best way control drug price market
encourag competit innov allow drug come
market fda initi set sight eas pathway approv
gener complex gener biosimilar lead us believ
gener space disproportion affect polici though
increas competit eventu affect brand drug line
scrutini orphan drug design remain especi wake
grow number blockbust orphan drug first approv narrow
expand broader popul rituximab humira
revlimid though concern come fruition last year fact
record number orphan drug approv recent attent
fda design process exampl allow applic proceed
miss inform popul size may add increas
pressur compani seek design go forward
effort increas transpar fda publish shame list
firm creat obstacl gener competitor though fda
dictat price increas attent area could ultim provid easier
path gener entri road across indic
take overal regulatori trend continu look favor given clear continu push fda new treatment modal gene
therapi option patient slightli cautiou regulatori environ remaind given chang
leadership potenti restrict guidanc novel therapi approv nash somewhat less favor trend approv volum
though overal still see current environ benefit drug develop
updat stanc regulatori landscap influenc number event
gene therapi continu hotb activ earlier
year zolgensma approv mark continu gene
therapi emerg follow reveal price tag
fda interim commission ned sharpless even critic
pushback price refer treatment almost
magic miracl reiter enthusiasm
follow concern
subsequ approv conting observ
feasibl studi view exampl fda/th
medic commun continu open new option even
risk
acut steroid-refractori gvhd
base primarili single-arm trial approv
follow pdufa delay even
random data indic expect
highlight fda willing move forward limit data
benefit
clear though jakafi previou market
establish may made easier
approv jnj spravato esketamin treatment-resist
depress highlight fda willing consid mix
data psych studi could read coverag
later year also potenti de-risk sage
pend readout unfavor
previous highlight scott gottlieb pro-innov
initi clear posit sector whole thu
departur leav potenti larg shoe fill gottlieb
support sharpless successor remain seen
sharpless
follow gottlieb footstep polici
recent releas nash guidanc weigh somewhat
space demonstr uncertainti fda use
histolog endpoint basi nash asset approv
note
like consid nash drug
tradit approv pathway time certain patient
fda would consid trial basi
acceler approv
imgn mirvetuximab come
surpris us base high unmet need platinum-
resist ovarian cancer well appar improv
standard care
kpti selinexor saw unfavor split adcomm vote
wait
random boston data avail
potenti approv r/r multipl myeloma pdufa set
juli follow fda request addit data
govern shutdown december/januari could
view one-off event like slow regulatori progress
somewhat number compani highlight polit
risk like becom pronounc
move closer elect
number nme bla approv track lower
approv also track lower
pick back
though smaller sampl far
approv rate trend
approv nme new project approvalsnm project biotech outlook halftim report tide lift boat
acceler approv track slightli year
fda histor select
acceler approv
trend continu year
far acceler approv
grant js balversa roch
acceler approv grant
indic poor prognosi
treatment rare diseas far
year acceler approv
cancer treatment bladder cancer
dlbcl
companytickerdruggener nameindicationapprov datereview prioriti orphan statusapprox popul phasedatatri designmerckmrkkeytrudapembrolizumabmetastat orr pr patient random dose test johnson line mo pt random open-label studi dose test intercepticptocalivaobetichol line iiialp reduct pt placebo-control randomizedsarepta srptexondi exon placebo mep higher pt random placebo control pt open-label single-armclovisclvsrubracarucaparibr/r brca mut ovarian recist brca mut pt single-arm open labelastrazeneca aznimfinzidurvalumabadvanc bladder yrphase orr cr pt single-arm open-labelcelgenecelgidhifaenasidenibr/r mutat yrphase orr cr mo median os pt open-labelportolaptlaandexxacoagul factor xarevers factor xa inhibitor-rel yrphase decreas anti-factor xa activ placebo control studi amikacinnon-tubercul mycobacterium yrphase sputum convers refractori pt placebo-control approv grantedacceler project biotech outlook halftim report tide lift boat
number breakthrough therapi design track slightli
breakthrough therapi design per year approv appear
level steadi climb sinc
all-tim high breakthrough drug
approv look trend downward
data march
breakthrough drug approv breakthrough design grantedbreakthrough full year project request grant orphan drug design approv trend possibl due
reduct backlog
number orphan drug design grant orphan drug
reduc number orphan drug
design grant
impli fda
larg work
start
even lower number
number orphan drug
approv line
scott gottlieb state goal
includ uniqu indic separ approv
drug design grantedorphan drug project mani regulatori event outlook favor outcom
companydrugeventtimingnot label features/regulatori event monitorkptiselinexorsubmit condit approv penta-refractori hccjanuari drl ipr md mou patentsfebruari reject alxnultomirispdufa pnhfebruari approv decemb date acut gvhdfebruari follow pdufa delayregndupixentpdufa ad adolesc sbla march lotu ipr mm mou patentsmarch reachedsagezulresso brexanolon pdufa target date zulresso ppdmarch box warn sedat loc in-lin expectationsaldr eptinezumabbla file rrm ind infantil batten diseas date selinexor penta-refractori mmapril juli follow split unfavor adcomregnpraluentpdufa cv risk reduct sbla april hyperlipidemia sbla april diabet retinopathi sbla may submiss decis decis inclus mainten treatment ovarian cancer eu sbla pre-fil submiss peanut allergi file us eu jp file pomp decis upcom notabl regulatori event
companydrugeventtimingnotesregndupixentpdufa crswnp sbla jun approv soliri nmosd pdufa june mmpdufa date selinexor penta-refractori mmjuli adcomm schizophreniajuli potenti us approvalaug atezo abraxan non-suam nsclcsep date myelofibrosissep adcomm meetingsep pdufa data schizophreniasep nda file nda tripl combo file eylea pre-fil nda file ind file nda submiss nda file bipolar submiss nda submiss nda submiss alk-cmet amplifi nda potenti acceler approv r/r agili potenti bla file feedback insomnia add ind decis drug price polici
materi trend less like
draconian chang drug price may still fear occur remain unlik
even light increas increment reform possibl congress
govern posit intervent unlik central bodi
coordin capabl develop meaning price measur
biopharma industri modestli improv abil commun valu
organ messag price strategi intent vs player
pbm though on-going improv would still benefici sector
new value-bas initi novel strategi author gener could
continu improv reimburs paradigm new market entrant offer
pressur affect sector market
improv comprehens awar price reimburs
certain therapeut area continu stay protect larger competit
market remain expos payer target class sever therapeut option
cost contain opportun continu see orphan drug certain oncolog
class insul
high appar pre-negoti fda-endors price launch
gene therapi mainten hiv drug within protect class
demonstr open favor reimburs high-valu product
polici expert weve spoken see increas likelihood drug price area
could see cooper recent held
unconstitut percept polit risk space could amplifi though
legal decis like mani year away unlik result major
chang view
trump administr aggress pursuit
drive price chang
includ emerg involv fda price debat public scrutini
alon influenc frequenc magnitud compani will
potenti congression hear especi democratic-control congress
state drug price transpar initi continu ramp well increas
begin presidenti campaign like renew nation attent
complex new entrant car-t gene therapi like add fuel
debat therapeut spend despit focu valu new price deliveri
model may take time establish
drug price especi healthcar key mid-term elect issu
competit market like particularli expos payer target therapeut
area sever option cost contain opportun formulari placement
valu outcomes-bas price reauthor tool payer
dispos like impact specialti area biotech play
tradit insul market like ms hiv begin see somewhat
increas formulari manag though see rel low-risk attempt deriv
plan cost save therapeut area strategi unlik stray
far clinic guidelin
substanti cgrp discount prolong orkambi uk negoti illustr risk
reimburs crowd class intern
take administr continu aggress approach drug price multipl govern committe hear taken place
topic recent continu believ draconian chang reimport central part negoti etc unlik said self-pol
evid alreadi account decreas abil use drug price lever growth go forward percept around
increas rhetor elect even like amount major chang like continu keep mani investor sidelin
modest uptick price recent though public privat stakehold continu exert influenc
biopharma neutral abil util price drive sale
mani compani took measur price increas and/or chose implement later earli
januari public/media focu high
expect continu scrutini commerci payer govern side aisl galvan
around drug price spend exert influenc manufactur
expect price-driven growth remain check see signal relief price pressur return
old way price increas legaci drug prop biotech revenu growth
histor averag sales/trx monitor biotech product show shift
price growth sale driver
trump administr activ suggest chang feder drug program
still rel low impact term compani bottom line potenti cumul
effect chang drugmak worri
may hh final rule requir manufactur disclos wac price televis ad first
trump blueprint idea implement though polici current challeng district court
lawmak held recent public hear aim pbm payer drug manufactur though
consensu appear exist effect reduc drug price
executivecongressionalblueprint strategyactionactioninitiativepart dpart bmedicaidprivatex increas oversightxxxban pharmaci gag clausesxxxxremind part patient toolsxxxbiosimilar action planxxxxxincreas gener approvalsxxxxxrem abus shame listxxxxxguid citizen petit anti-trust reviewxxxxximport sole sourc drugsxxxxxorphan drug design clarificationsxxxxxindication-bas managementxxstep edit medicar part bxxconsolid part d/b programsxxxintern price payment modelxxomb rule chang anti-kickback statutexxincreas formulari flexibilti protect classesxxcm dashboard increas price transparencyxxxxxend price reset line extensionsxx disclosur list price dtc advertisingxxxxxrep ipabxxxmedicar part donut hole changesxmedicarelow out-of-pocket costscreat incent lower list pricesotherincreas competitionstrengthen negoti biotech outlook halftim report tide lift boat
state initi around price regul transpar remain worth watch
number state also pursu legisl combat rise drug price subsequ litig
surround constitution approach ca sb import monitor
stateinitiatived manufactur prescript drug give notif day advanc price increas wac increas exceed two-year period quarterli report justifi wac increas list wac increas period five cost new drug exce medicar part specialti threshold requir manufactur notifi state least three day launch submit report detail price market plan day later assembl manufactur provid subsidi copay pocket expens therapeut equival provid patient insur louisianaact must document report wac drug market state dept must compil list essenti diabet treatment identifi drug price increas exceed cpi cpi medic indic identifi manufactur requir submit report detail factor wac increas provid inform cost product market advertis profit pbm must submit list prescript drug sale rep identifi sale rep must provid report detail yearli compens drug sampl provid new drug expenditur exceed annual growth limit ny dept may identifi drug supplement medicaid rebat request manufactur request target rebat target rebat provid manufactur must report cost manufactur distribut market advertis price rebat offer compil list drug state spend signific health care dollar wac increas year year manufactur must justifi attorney gener reason price wholesal import program import predetermin high-cost pharmaceut canadawashingtonhb sb legislationrequir manufactur submit specifi data drug increas price one year past three year also allow privat organ collect verifi report price data massachusettshb sb hb legislationmanufactur would need justifi price increas year year offic attorney gener also requir manufactur top sell drug state provid detail report manufactur cost market cost cost privat public purchas illinoi sb session sine die tabl indefinit manufactur requir notifi public privat purchas least day price increas requir manufactur specifi price new prescript drug day commerci avail allow depart public health publish inform internet pennsylvaniahb sb on-going legislationestablish pharmaceut transpar commiss would determin whether retail price drug reason pbm insur would need pay premium commiss determin reason cost also would requir manufactur sell drug state provid annual report cost market consum rebat vermontsen result on-going lawsuit investig government initi could broad read-through
eventdescript impactsen gao investig orphan drug price last year senat hatch grassley cotton submit letter govern account offic gao concern pharmaceut compani may take advantag orphan drug act oda specif cite multipl design allow orphan drug act potenti problem gao accept request expect begin investig near end updat investig releas investig examin drug expand beyond orphan indic whether oda actual incentiv develop drug orphan indic provid recommend regulatori legisl chang preserv intent law given increas scrutini surround orphan drug believ investig worth follow given potenti neg ramif compani current util oda ir investig charit donat patient assist chariti ir recent step investig practic drug manufactur donat patient assist chariti donat chariti help patient afford expens co-pay necessari medic may violat anti-kickback law sinc drug compani directli benefit donat use purchas drug made manufactur agre pay settl lawsuit doj violat feder anti-kickback statut similar on-going whistleblow lawsuit celgen face alleg money donat chariti intent steer contribut toward drug lead charg improv drug price confirm secretari hh januari vocal propon trump administr american patient first blueprint lower prescript drug price element blueprint includ propos give feder govern power negoti drug price move medicar part drug part remov barrier gener drug competit requir drug price disclos tv commerci recent senat hear presid blueprint field question numer senat express frustrat lack immedi impact drug price perceiv limit negoti power outlin plan inabl administr offer discret timelin initi begin benefit american drug discount program larg cap limit exposur though continu monitor movement percept public payer front pricing/reimburs overal potenti headlin risk believ chang purchas paramet would meaning read-though time biotech outlook halftim report tide lift boat
see ex-u ip workaround revoc unlik worth watch could erod
negoti reimburs vrtx orkambi uk stall sever year
continu failur achiev agreement could drive uk take addit action includ crown use licens
patient uk report june attempt form cf buyer club could purchas
gener orkambi manufactur argentina notabl less vrtx report offer
though patient would still pay out-of-pocket may possibl due uk law note import
medicin legal person use vrtx lack patent argentina
negoti lever essenti forc provid orkambi cf therapi meaning discount
england could caus eros price power european countri well
could tangibl impact cf revenu tail also potenti creat uncertainti around intenational price power
premium-pr orphan drug gener
howev sever mitig factor specif case
decis invok crown use licens would like take number year success bring uk-
manufactur gener market nh could cover given ramp-up requir manufactur need
expect could legal challeng cf buyer club go argentina addit
import medic would still undermin purpos nh healthcar equal price would still
high patient addit qualiti profil import gener product unknown
advanc vrtx tripl combo therapi would improv valu proposit significantli could
make current uk price debat orkambi less relev
wane collect annual list price increas prior year remain base case though
rate declin slow price growth lose influenc concept disciplin
price becom broadli accept dynam
note analysi includ product celg relev competit
materi trend less like
mani resourc strategi
extend life cycl key product key detail remain scant
mani key patent expiri think specif may
emerg come year potenti settlement celg
revlimid combo/formul strategi inci jakafi
dispos
mani biotech yet elucid exact pathway
plan manag key life-cycle patent cliff limit progress
toward aim either product extens diversif
time act continu shorten
greater regulatori anti-trust scrutini enabl faster pathway
backlog anda could continu cap longev biotech
number favor procedur chang ipr process
new director patent offic posit patent
fda implement number initi improv
speed biosimilar gener reach market uptak
rel slow
take advanc key life cycl manag strategi strateg transact ip lawsuit settlement remain pertin
patent cliff inch closer believ increasingli imper large-cap compani make substanti progress life cycl pipelin
develop posit side favor uspto polici help brand drug manufactur better defend patent
portfolio time
mani legaci product large-cap biotech begin face patent cliff within next
year increas investor concern base busi franchis maintain off-set
biib tecfidera renew concern around dose patent light mylan ipr less-than-
expect patent term extens worsen potenti backstop lack clariti sustain ms
franchis life cycl manag strategi
mani biolog product face biosimilar entrant though success
kept bay lack approv bpcia litig product sensipar vectibix
nplate also face gener come year
inci jakafi jakafi inch closer potenti patent expir
celg revlimid gener entri start full generic potenti
greater entrench earlier entri depend outcom on-going anda litig
gild hiv franchis taf go gener uncertainti remain around
mainten hiv market domin possibl brand dolutegravir gener f/taf compon
use altern
alxn soliri eu soliri face potenti biosimilar entri
regn eylea potenti off-pat
clvss rubraca street disagr valid polymorph patent could place patent expir
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
patent cliff mind believ celg made progress
year wherea still face signific hurdl
favor outcom on-going ipr
settlement lotu pipelin
markman trial outcom anda
posit filgotinib descovi prep
generc truvada launch
advanc
on-going switch
formul patent
long develop timelin
approv competitor biosimilar
expand indic footprint
expans eylea dose
clinic oral antagonist
advanc ruxolitinib sr
formul combo busi
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
given still see multipl strategi large-cap biotech implement litig optim
diversifi medium term
ip regulatori
bpcia anda litig settlement
novel formul less frequent
conveni dose
citizen petit rem
new mode administr
clinic approv hurdl
next-gen product improv efficaci
supplementari ip dose regimen
strateg divestitur diversif
payer agreement reimburs
new patent offic director continu implement favor chang ipr process
new uspto director announc number procedur chang patent trial
updat claim construct standard broadest reason interpret standard narrow
phillip standard align conserv approach use district court
propos new amend procedur give opportun amend claim proceed
simplifi requir patent elig recent case law develop caus lack clariti
overal chang wont like appli retroact on-going ipr like biib believ
long-term yield favor result brand drug manufactur defend patent
gener compani
addit trend favor patent owner could also continu implement come year
pendulum swing back emphasi patent qualiti toward innov protect
congress recent began review patent elig requir would favor provid
clear protect biolog invent
continu strengthen foreign ip strength new trade agreement tariff pressur
new uspto director like continu implement posit chang ptab includ potenti
higher standard review limit serial challeng etc
suprem court still potenti review outstand aspect ipr retroact applic
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
materi trend less like
redefinit address market via person medicin
approach continu enabl biotech rapidli grab
maintain foothold certain nich higher likelihood
minim competit premium price power
area io combin therapi like becom
futur mainstay competit could creat incent consolid
larger compani backbon therapi may seek maintain
leadership incorpor adjac drug technolog
larger compani look establish enhanc posit
therapeut area may look acquir biotech compani
market even novel product class like becom increasingli
emphasi minut product differenti biotech commerci prowess
success execut upon launch price potenti pressur
nuanc smaller expect address patient pool slower
perhap previous lofti expect biopharma
expect product
product revisit otezla yescarta kymriah
expect establish flagship product eylea biib ms sma
franchis emerg disrupt agent dupix may see
downward revis competit threat market posit better
crystal becom appreci
player compet group patient
enrol respect clinic trial mm dlbcl patient
car-t bispecif ab product develop
competit coupl favor regulatori environ
maintain trend
gener biosimilar brand
like
take competit biotech spur new fda approv brand biosimilar product payer initi
aggress discount market cgrp anti-vegf remain headwind sector expect
trend continu intensifi across sector addit entrant payer leverag competit dynam reduc drug cost
presid trump blueprint contain sever initi spur gener biosimilar competit
self-pol evid though blueprint implement slow
seen overarch trend greater restraint consist
expect increas self-pol biopharma compani
current environ increas drug price scrutini
believ continu limit revenu growth compani abl
gener price rel volum
establish uniqu bill payment code biosimilar medicar
part encourag competit biosimilar manufactur
potenti signific impact
current develop biosimilar remicad rituxan avastin
herceptin humira
neulasta biosimilar competit increas
current receiv royalti brand rituxan revenu
significantli erod ex-u biosimilar competit biosimilar rituxan
entri expect
may hh final rule requir manufactur disclos wac price
televis ad first trump blueprint idea implement
sever key drug class experienc intensifi brand competit
signific potenti headwind biotech increas competit among recent approv brand drug
amgn aimovig new entrant ajovi emgal on-going competit free
drug program signific discount lower revenu approv space
expect begin aldr eptinezumab iv prophylaxi bhvn
rimegep agn atogep oral prophylaxi migrain
regn eylea experienc increas competit recent increas rebat
off-label brand avastin promot payer requir new avastin step-through
prior reimburs eylea signific increas reimburs avastin
creat attract margin addit competit expect near term nvss
brolucizumab potenti fda approv
multipl emerg competit threat gild establish hiv franchis
includ long-act inject recent approv str dovato viiv/gsk
novel nrtti bnab sni other though point believ
unlik substanti erod gild share
come note increas competit area lymphoma mm
car-t celg bispecif antibodi gsk
manufactur import competit dynam evolv addit
competit amgn repatha regn praluent led price
agent reduc attempt gain share revenu agent miss
street est
summari potenti underappreci disrupt forc across key therapeut class
discuss detail updat report game changer disrupt forc biotech
companyfranchis riskcompetitorspotenti disrupt achiev risk factorevobrutinib sanofi/principia gener therapi tecfidera generic ms therapi remov -- -risdiplam scholar takeda remov -- -earlier revlimid inhibitor f/taf generic antibodi truvada nrtti inject oral hiv cocktail gsk/viiv io off-the-shelf car-t sma celghivmultipl cartcompanyfranchis riskcompetitorspotenti disrupt achiev risk factorcftr mrna therapi modul pti gene edit workarounds/revoc oligo-ab conjug nippon shinyaku mini-dystrophin gene therapi microdystrophin gene therapi dmd gene editingvrtx/exon srpt/duke univers novel novo/gild atogep remov -- -ganaxolon rapastinel dmd therapydmd gene therapymigrain fibrosi biotech outlook halftim report tide lift boat
out-year street estim key product recent reduc may need revis
light emerg competit
long-term street estim key flagship product revis downward sinc earli
close match est believ reduct like increas recognit
long-term street revenu expect like
although previou lofti expect dupix
fulli account entranc multipl
therapi roche/ptct risdiplam
appropri come like room
still downward revis given intensifi
competit novel antibodi target
tslp oral jak inhibitor
rbcstreet earn growth
materi trend less like
price-to-earnings multipl lowest year like factor
lower growth worsen margin less diversif vs pharma
could see valuat reset pessim may result
overshot sector discount
one assum compani success deploy capit
 bd improv out-year growth align
broader market larg cap overal would appear attract valu
street estim look low could set-up strong earn
cycl calendar year potenti bottom-lin beat though
still room top-lin miss
base buysid survey result investor see core franchis like
vrtx cf product celg revlimid fundament strong
begin gain visibl toward hepc revenu stabil
regulatori submiss cf tripl combo signal like near-
long-term ep sale growth expect
larger-cap
biotech market product lowest year perhap
low enough matur franchis pend patent cliff
higher revenu base like much difficult large-cap
garner multipl histor
out-year margin compress complex product
partnership strategi vs could emerg theme
drug price increas less abl serv lever growth
like becom manifest start
street still neg key product launch space like car-t
though movement kite separ entiti may help off-set
somewhat
medium-term revenu growth
aducanumab failur mechan earn growth
start see revenu growth jakafi expand
potenti srpt exon-skip franchis golo- pdufa casi-
take long-term growth prospect look promis mid-cap biotech large-cap compani larger biotech continu
work grow pipelin contribut larger revenu base though current valuat among mani commercial-stag compani still
look like may overli discount dynam
large-cap biotech price-to-earnings multipl remain continu look favor vs
broader market increas attract low valuat could draw generalist
note large-cap biotech includ celg
near-term large-cap biotech ep estim increas out-year ep
revenu project declin
could reflect optim around expect new product launch vrtx triple-combo near
term long-term effect increas competit regn dupix remov potenti
aducanumab revenu model
note consensu celg
larg cap biotech -- histor ep consensu estim larg cap biotech -- histor cumul sale consensu estim investor view vrtx cf franchis regn dupix gild hiv franchis like
beat amgn aimovig biib spinraza pbyi nerlynx like miss
spinraza aimovig rubraca soliri hiv franchis cf franchis kalydeco/symdeko/orkambi select key product franchis estim like beat misslik misslik averagelikelyto beatlikelyto miss survey investor vs view potenti beat miss key product
note consensu estim obtain factset
expect sale ep growth large-cap biotech low may still room
miss especi long term
see ep revenu growth slightli lag consensu estim onward
long-term margin compress worth watch
number driver make us anticip out-year margin compress long-term headwind worth watch
sector
shift toward complex product like car-t gene therapi higher cog vs
histor small molecul antibodi
exampl like face margin pressur hcv declin continu hiv becom
larger proport base busi
higher oper expens associ build-out commerci manufactur infrastructur new
increas use partnership strategi royalti could also weigh growth
materi trend less like
influx new manag member across larg cap biotech
re-ignit idea gener busi develop
potenti investor enthusiasm provid fresh perspect
execut chang across large-cap biotech like perpetu
transition/inst could keep investor
percept
sidelin least respect strateg direct becom clearer
preponder execut come larg pharma
diversif ip reimburs challeng face matur
trend toward legaci large-cap pharma biotech execut move
downstream lead emerg privat small-cap compani could
continu attract
influx smaller
compani within space given scientif development
credibl provid
investor interest capit
turnov mid/smid-cap biotech enabl stabil within high-
like continu attract major
movement execut big pharma large-cap biotech
highlight fact
organ matur
composit earn growth profil like
view valu akin slower-grow less-diversifi
sometim consider manag premium place early-
stage non de-risk compani well-regard leadership could
make valuat fragil exagger potenti downsid
compani peer experi setback
remain scarciti talent experienc individu
emerg area like gene therapi could increas personnel
cost slow develop
take may necessarili enough complet turn sector sentiment around influx new manag member larger biotech
gener well receiv becom establish respect compani provid fresh perspect strateg
clariti believ help foster improv capit alloc portfolio diversif continu see manag premium place
chang make stronger larger biotech seen signific senior manag turnov
recent year execut often larg pharma becom settl
old
new
head op jim meyer
head op anthoni hooper
head op murdo gordon
one make trend
increas preponder personnel big pharma addit intern promot
candid reflect matur compani increas need focu challeng
market access competit reimburs share larg pharma co
grow import manag complex organ shepherd bd small
corporate/busi develop effort longer adequ given high revenu base
build need veteran cfo bd leadership
oper commerci increasingli complex navig requir understand
reflect need fresh approach run busi alloc capit given
stagnat valu creation
gener less turnov smid/small-cap high-growth mid/larg cap compani
high growth opportun and/or rare diseas focu less
crowd domain continu emphas clinic execut
second act legaci exec larger-cap acquir small-cap compani move
increasingli emerg privat public compani
exampl
leadershipnext endeavorjacki fous former celg presidentagiosandrew cheng former cmoakeroform alio executivesaligosform zs pharma executivesakosform kite executivesogeneform naurex executivesaptinyxscott smith former celg presid coobioatlajeff kindler former chairman ceocentrexiondoug william former head dcodiakalessandro riva former oncolog headglenmarkform recepto executivesgossamerform actelion executivesidorsianorbert bischofberg former cmokronospaul friedman former presid ceomadrigaljeremi levin former teva ceoovidform idix executivestransl biogeorg scango former ceovir biotech outlook halftim report tide lift boat
experienc leadership provid veteran acumen stewardship help foster investor
recent year seen mani legaci larger-cap acquir small/mid-cap
biotech senior execut move privat emerg compani includ spinoff
version prior compani leverag scientif clinic develop
instil much-need expertis early-stag compani often seen provid
strong valid platform portfolio attract investor interest
believ remain import balanc continu favor presenc well-
respect leadership risk substanti personnel premium rel extent de-
risk asset technolog leav open potenti magnifi downsid
materi trend less like
need larg biopharma chang narr slow ep
growth pend patent cliff remain high rel favor
cost capit high cash posit enabl
pressur may potenti grow even greater vs
manag commentari vocal desir pursu
deal larger-scal bolt-on acquisit given mani larg
biopharma compani complet restructur and/or new
manag place could increas focu deal
recent resurg deal flow though perhap still
investor expect could begin resurrect
 could draw investor attent away matur core
franchis particularli smid-cap biotech whose valuat
would like benefit increas expect premium
sinc fade earlier enthusiasm
complex manufactur longer
demand drive premium higher competit bid
revenu tail
larg biopharma continu leverag cash primarili dividend
share buyback pose question industri overal commit
meaning
larger revenu base like difficult off-set singl smid-
cap deal diminish earn power deal rel
valu paid could also disincentiv least compani
fulli de-risk
industri check indic except gild/kit
may grow predilect toward smaller earlier-stag deal
would transform much longer term structur
partnership structur may mitig risk though like
larg cap compani add pipelin
diversif histor proven less favor smid/mid-
cap co reduc perceiv likelihood ultim acquisit
higher valuat among mid-cap could keep industri focus
take believ rel strateg capit deploy strong cash posit pipelin need improv manag
stabil continu support activ though believ predict major deal remain difficult major smaller earlier-
stage bolt-on light favor valuat may suffici catalyz sustain sector momentum
number expect unexpect takeout alreadi taken place year
part stock view like taken
driven out-performance large/mid-cap
higher make possibl takeout less like
mani investor view large-cap consolid less like
surpris bmy/celg deal large-cap
pharma indic like one-off situat still
continu watch possibl large-scal merger
select like takeout candid biopharma manag continu bullish note plan activ key
strateg aspect long-term valu creation though slight bia toward earlier-stag bolt-on
companyrec sentiment commentsselect recent bdllydavid rick ceo investor hc confer compani good cash-flow-gener posit low level debt high rate see quit bit capac deal agnost whether collabor realli interest asset realli enhanc posit five core therapeut area loxo armopfejohn young call think youll see us continu activ busi develop think focu gener earlier mid-stag opportun certainli term size continu consid bolt-on think would say asset rang billion dollar would continu consid bolt-on acquisit realli complement pipelin excit opportun that someth particularli go focus month ahead arrygskemma walmsley call first notic reason busi last quarter term busi develop number one focu make sure deliv valu deal said extrem clear juli number one prioriti strengthen pipelin im pleas progress bd continu key part tsrogildrobin washington cfo investor hc confer got robust bd engin spent lot time to-dat think come speed heard talk rel focu capit alloc look bd primari area focu think activ week think get even insight thought area go forward start unveil strategi extern biibmichel vounatso ceo investor hc confer capabl organ term bd enhanc activ look opportun cover broad rang type deal say sweet spot remain baselin well cash flow gener high burn platform disciplin manner continu nitecompanyrec sentiment commentsselect recent bdjnjjoseph wolk cfo investor event continu activ evalu potenti deal strateg financi oper len ensur deliv fair return sharehold mrkrobert davi cfo day much add continu prosecut market fulli lot discuss go mani case still find often see will seller go continu deal confid go continu find opportun would say appetit less larg deal mid-to-smal deal imdzabbvmichael severino vice chairman presid investor hc confer go look earli stage deal add earli pipelin thing seen us recent recent found valu early-stag deal thing pre-proof-of-concept either move toward clinic earli clinic develop go look across set small medium larg opportun assess see valu nvsvasant narasimhan call think mind open fact order build valuabl compani time bolt-on part strategi along line portfolio that way go approach avx ecytamgndavid melin cfo investor hc confer basic reason transact look price valu equat acquisit abl make busi case deliv promis pass unfortun later-stag deal optimist see come fruition futur seen opportun better valu case earlier-stag opportun continu oper bmycharl bancroft call regard busi develop near-term plan continu look smaller earlier deal balanc sheet reset capac addit bd celg valuat among smid-cap higher begin year pull back earli
buyback though dividends/buyback still continu key strateg prioriti
dividend steadili increas among biopharma share repurchas mostli normal last year
substanti post-tax reform increas except like
said despit activ nv roch biopharma still flush cash biopharma
may consid worthwhil use capit alloc given limit valu gener share buyback
note price
lower deal volum overal deal valu compar time last year
larg biopharma seem prefer smaller earlier-stag deal privat compani discount late-
stage asset oppos larger acquisit histor seen space
higher profil acquisit multipl bidder demand higher premium vs
lower valuat like influenc total transact size
said expect current pace deal-mak continu increas pressur biopharma
compani could increas demand drive premium
total deal valu track compar last year despit lower volum indic potenti
hand meaning size deal back half year
note deal valu total exclud takeda-shir deal deal valu total exclud celg-bmi deal graph base announc date
number biopharma deal juneful deal valu biopharma dealsthrough juneful year biotech outlook halftim report tide lift boat
despit large-cap biopharma enthusiasm fewer larg deal compar time last year
number announc deal reach vs time total valu deal
rang lower vs point last year vs
expect addit large-scal typic see one deal scale per year
view celg-bmi deal indic broader consolid trend industri manag
team indic desir pursu type strateg initi instead choos pursu bd
mid-to-earli stage pipelin asset sell under-perform busi
roughli equival averag deal valu though higher premium indic competit bid
prefer lower price target early-stag bolt-on privat compani
public biopharma premiummillionscumulat deal valu public biopharma dealstot valueaverag day premium biotech outlook halftim report tide lift boat
biopharma acquisit public biotech
deal highli focus oncolog emerg gene cell therapi platform
continu trend though slightli slower pace
compani manufactur technolog emerg target oncolog platform seem high
interest sector warrant higher premium
expect see addit deal oncolog neurolog potenti nash
materi trend less like
believ continu scarciti valu increasingli favor
valuat bode well innov late-stag platform-bas
compani seek ipo
anticip fewer ipo due decreas demand follow
especi among earlier stage
record-break year
valuat abil rais capit follow-on offer
heel posit data readout continu favor
increas access privat capit sustain vc-fund privat
biotech continu creat robust pipelin potenti futur
risk dilut due healthi size number
offer though could off-set upsid posit data driven
upward excit new technolog
anticip capit rais temper upsid data catalyst
limit favor valuat time follow-on offer
increas capit need sector remain worth watch long-term
high level privat public invest could limit
level overexuber early-stag modal could increas
risk financ slowdown hiccup
fluctuat valuat public market decreas privat
therapeut area demand novel modal rare
take ipo market activ continu robust notabl shift toward high-opportun therapeut area
strong valuat even though post-ipo perform mix overal public privat invest space remain
strong bode well continu innov fund new technolog though slightli decreas privat invest
oversatur remain risk watch
ipo activ robust continu last year trend
despit particularli activ activ sustain last year momentum roughli
equival number ipo amount rais ytd
rel early-stag compani continu receiv favor valuat though ultim may shift
compani innov modal later-stag may greater abil
capit public equiti market
earlier-stag modal continu abl go public without matur data hand believ
could pose risk post-ipo perform valuat align close reflect valu
note price
biotech ipo gross proce number rais per ipo gross proce ipo rais per ipo biotech outlook halftim report tide lift boat
ipo market continu reflect increas innov sector continu scarciti valu
appetit sector though increas focu lower-risk higher-reward therapeut area
cancer remain hot therapeut area invest repres biotech ipo
ipo across cell therapi io target oncolog acquisit loxo arri support
perform latter
neurolog ipo metabol ipo focus compani also promin among go public
histor popular certain therapeut area emerg technolog modal rare diseas
sirna/mrna gene therapi wane investor appar shift focu within new issuanc
broadli address market nash parkinson cancer
note price
biotech ipo perform offer price areanumb iposperform offer biotech outlook halftim report tide lift boat
capit need continu stabl thu continu met though area
continu monitor
estim number compani less month cash thu like need rais
come year similar year-end level vs vs
said amount cash burn per quarter entir sector steadili increas
number public compani increas compani progress later stage requir capit
clinic develop clinic develop cost increas
overal total amount rais per follow-on decreas y-o-i perhap reflect
worsen valuat also observ ipo market
light potenti increas strain public market compani requir access capit
increas cash use continu monitor health capit rais environ given
privat public appetit seem remain high amount rais follow-on far exceed amount
need sector forese major difficulti follow-on market come year
note price
ytdtotal rais follow on number rais per cash burn cash burn biotech outlook halftim report tide lift boat
privat biotech invest appetit decreas compar prior year
despit strong ipo market seen decreas pe/vc invest biotech space compar
time-frame last year repres less half total capit invest space
think public privat invest space maintain continu support ipo
pipelin though on-going flurri ipo year overal invest could continu stabil
addit public market focu larger market indic could alter privat market focu limit
invest specif diseas area though overal high-qual innov technolog continu
abl find fund fuel futur ipo pipelin
note price
ytdtotal capit rais total biotech capit investmentiposfollow-onspriv ytd biotech capit investmentiposfollow-onspriv placementvctot capit rais right axi total biotech capit invest capit rais right innov
materi trend less like
continu launch new product class cgrp spinraza
help signifi biotech abil maintain top-lin diversif
organ growth via success invest innov
base busi come
emerg
increas preval new therapeut modal gene
frontier
therapi car-t mrna bring focu next
medicin therefor new attract growth opportun
govern vc fund academ research compani
creation continu sustain
market innov therapi without sacrif risk/benefit
requir maintain high barrier entri
transit develop
increasingli complex therapeut
enabl expans previous untreat diseas thu
gener new market opportun well protect
patent risk maintain higher barrier entri increasingli
number innov remain earli stage develop
yet face test clinic creat long-term invest horizon
 clinic setback remain realiti novel
technolog continu broadli experi could dampen
sentiment invest innov biotech aducanumab
new modal like gene therapi car-t
approach deliveri reimburs could take system
time adjust get necessari infrastructur place addit tend
lower margin product
transit clinic stage may prove difficult particularli given
challeng manufactur product
therapeut along talent scarciti hurdl creat
futur declin govern spend support research
declin investor appetit support earli stage biotech
fewer blockbust launch number make-or-break clinic
catalyst emerg therapeut area like nash neuropsych
key point could temporarili dampen investor enthusiasm around new
therapeut area neg
take core fundament driver biotech sector d-fuel innov remain intact believ high profil setback
alzheim nash put greater onu innov larger biotech like invest compani
creation overal continu flow healthi pace innov perceiv occur small/mid-cap biotech larg
pharma within large-cap biotech
see continu focu commerci launch sever key product new
on-going launch amgn
on-going launch label
expans nv kymriah
acquisit rhhbi
avx gene therapi
convers rate patient
potenti switch real-
competit oral cgrp
regul amen surrog
price baselin gene-
logist administr
technolog improv
treatment monitor follow-up
saw mix result seri key clinic catalyst particularli nash neurolog
modul enthusiasm therapeut area addit readout expect
data stellar stellar ph iii
studi selonsertib nash
interim ph iii data icpt regener studi
oca nash
sage read ph iii data
potenti interim analysi ph iii studi biib
aducanumab alzheim
data ph iia studi enta nash
data ph iii studi itci
lumateperon bpd
atla ph iib data selonsertib nash
agn ph iii rapastinel data mdd
phase data gnft ph trial
possibl alzheim crenezuamb interim
early-stag novel therapeut modal refin exist class continu emerg
therapeut antibodi
ai improv target optim lead select small molecul antibodi
boom pipelin complex therapeut antibodi bsab fc-fusion protein adc
saw increas t-cell engag enthusiasm come
target diseas
on-going improv car-t improv upon efficaci safeti conveni on/off switch
expand crsp collabor acquir exon advanc dmd gene edit program
mani parallel approach zinc-fing nucleas increas likelihood could
see gene approach becom mainstay form treatment assum manufactur safeti
hurdl overcom
year develop number viabl rna-target therapi reach market
mrna year-end ipo potenti class may yet fulli recogn enthusiasm
precis medicin
combin i/o chemo target therapi area develop surround increas
excit initi suffer setback inci epacadostat nktr howev
indic implement may simpl initi thought
precis medicin approv loxo astella etc site-agnost label breast breast
etc appear increas traction expand new regulatori approach class
emerg trend industri on-going shift toward complex therapeut
shift toward complex biolog agent cellular therapi gene therapi
continu fuel innov space result
product higher barrier entri due level know-how complex need manufactur
develop
overal lack tradit patent risk seen small molecul simpler biolog
abil treat previous untreat diseas even cure instanc better address
area unmet need improv upon current treatment paradigm
light chang innov environ see number key hurdl worth watch
scarciti area like gene therapi especi problemat ensur strong oper
excel given high degre complex space
manufactur scalabl challeng transit clinic commerci stage
margin compress discuss earn growth section
could see catalyst relat number innov plu
ph iii mountain studi
split congress work togeth
zuranolon mdd
continu launch first gene therapi
continu negoti china
mexico trade tariff
multipl data readout nash
oraxol data breast cancer
potenti continu
vosoritid readout
eyelea pre-fil syring
soliri nmosd pdufa
potenti celg settlement drl
dupix crswnp pdufa
slow ipo pace
pdufa
investor expect key sector catalyst mix
investor see pfe dmd gene therapi express safeti data read inferior srpt microdystrophin
data sage data show sign activ make acquisit like occur
investor see lose tecfidera patent challeng make acquisit least like
occur
make acquisit ultim lose tecfidera patent challeng mylanamgn receiv favor rule enbrel ip litig vs sandozagio data mtap-delet tumor show clinic meaning anti-tumor activ across multipl tumor typesimgn forward data mirvetuximab like esmo demonstr clinic meaning delta vs chemo inlate-lin high fr atnx oraxol readout august metastat breast cancer demonstr superior orr vs iv paclitaxelgild make acquisit earli stage bipolar depress data show sign activitypf dmd gene therapi express safeti data expect inferior srpt microdystrophin data dateinvestor select key catalyst like unlik occurunlik occurlik averagelik occurunlik occur biotech outlook halftim report tide lift boat
companydrugeventtimingregndupixentpdufa crswnp sbla jun approv soliri nmosd pdufa june brexanolon commerci launchlat jun itrmsulopenempre-plan interim analysi outcom potenti sampl size readjustmentend patent disput litig result gallop trial data vs data abound sqm trial squamou nsclc mainten nash hbv week extens data edelweiss trial data prolong part trial acut pretyerm stellar phase trial usher decis readout phase asthma studi cntrogarzoeuropean regulatori mmpdufa date selinexor penta-refractori mmjuli ph studi bipolar depressionweek juli adcomm schizophreniajuli result archway studi bpdjulygilddescovyfda adcomm prepaug potenti us approvalaug data trial trial updat reveal callcelgabraxanepdufa atezo abraxan non-suam nsclcsep date myelofibrosissep adcomm meetingsep pdufa date schizophreniasep data updat studi valrox hemophilia nash registr ph ii studi mcl nunuc data nda file adtop-lin data atop dermat iguana combosubmiss nda tripl combo data present forward trial oc like fda approv data atla phase combo studi selonsertib and/or and/or chronic studi snda file chronic dose rang data osteogenesi data implant trial data eu-bas primros trial uterin eylea pre-fil result mountain studi biotech outlook halftim report tide lift boat
data high dose cohort younger sanfilippo data phase claridhi trial tibsovo advanc cholangiocarcinoma data phase claridhi studi cholangiocarcinoma fda approv commerci launch peanut data atla trial data eclips trial data trial primari biliari ph patient cohort data establish b-cell potenti registr psp data karmma trial settlement gener anda cohort data cabo atezolizumab previous untreat -ktema regulatori decis kidney transplant ktregulatori updat fda dialogu potenti condit approv kidney gbminiti safeti efficaci data anti-gbm studi data forward ii triplet matur expans data addit aml bpdcn acut ph iii studi file full approv treatment-nav acut gvhd cholangiocarcinoma read top-line gbm combo inhibitor cemiplimab/libtayo bla submis dlbclpre-plan interim analysi b-mind studi data combin trial herceptin/endocrin herceptin/vinorelbin therapi er safeti potenti activ decis neratinib extend adjuv posit earli stage breast cancer indic phase data summit basket trial neratinib patient data set meet regul confirm phase readout dupix ad pediatr endpoint data pivot trial gene therapi myonexu data low dose cohort present medic data primros trial menstrual bleed associ uterin studi post-op acut bunionectomi pain preclin phase result first line low risk data myelofibrosi phase data part trial data phase b-cell cancer potenti late result trial launch enrol uuti cuti ciai pivot mmaddit efficaci safeti on-go dlbclbla submis l-mind data rr data proof concept sever data part trial data readout ph ii open-label studi low-dos rux combo mmtop-lin data ph iii boston studi outlicen result mountain studi combopotenti tripl combo contribut author
